Jul 17, 2023 · What is my cancer risk if I have a RAD51D mutation? A RAD51D mutation increases your risk for ovarian cancer. A RAD51D mutation may also increase your risk for breast cancer, but more research is needed for us to better understand this risk.

Mar 26, 2025 · Mutations in the RAD51D gene have been linked to increased risk for breast, fallopian tube and ovarian cancer. Researchers are studying whether these mutations increase the risk for other cancers. What can people with a RAD51D mutation do? Expert guidelines include recommendations for people with RAD51D mutations on managing their cancer risk.

Mar 26, 2025 · People with a RAD51D mutation may have different options for cancer treatment. Learn about the treatment options for people with mutations in this gene. FORCE is here to guide you.

Mar 26, 2025 · Women with a RAD51D mutation have about a 10-20 percent lifetime risk for ovarian, fallopian tube or primary peritoneal cancer (these three cancers and their risks are related and are often referred to together as ovarian cancer).

RAD51 is an ATPase that forms a nucleoprotein filament on single-stranded DNA. RAD51 has the function of finding and invading homologous DNA sequences to enable accurate and timely DNA repair. Its paralogs, which arose from ancient gene duplications of RAD51, have evolved to regulate and promote RAD51 function.

Mar 30, 2025 · RAD51D (RAD51 Paralog D) is a Protein Coding gene. Diseases associated with RAD51D include Breast-Ovarian Cancer, Familial 4 and Hereditary Breast Ovarian Cancer Syndrome. Among its related pathways are Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) and Homologous DNA Pairing and Strand Exchange.

While a RAD51D mutation means you have a somewhat higher risk of developing cancer than the average person, it may not fully explain why your blood relatives have cancer. As we learn more about these mutations, we may learn they increase the risk for other types of cancers.

RAD51D Mutation is a predictive biomarker for use of olaparib in patients. Of the therapies with RAD51D Mutation as a predictive biomarker, 1 is FDA-approved and 1 has NCCN guidelines in at least one clinical setting.

Here, we have reviewed the landscape of RAD51C and RAD51D germline variants in cancer reported in the literature during the last decade, integrating this list with variants identified by in-house patient screening.

RAD51D is involved in DNA double-strand break repair by homologous recombination and plays an important role in the maintenance of genomic stability. The associations between RAD51D germline mutations and breast cancer risk and survival are not fully elucidated.